These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22959989)

  • 1. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
    Dayan GH; Bevilacqua J; Coleman D; Buldo A; Risi G
    Vaccine; 2012 Oct; 30(47):6656-64. PubMed ID: 22959989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.
    Biedenbender R; Bevilacqua J; Gregg AM; Watson M; Dayan G
    J Infect Dis; 2011 Jan; 203(1):75-84. PubMed ID: 21148499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.
    Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP
    Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live, attenuated recombinant West Nile virus vaccine.
    Monath TP; Liu J; Kanesa-Thasan N; Myers GA; Nichols R; Deary A; McCarthy K; Johnson C; Ermak T; Shin S; Arroyo J; Guirakhoo F; Kennedy JS; Ennis FA; Green S; Bedford P
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6694-9. PubMed ID: 16617103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.
    Durbin AP; Wright PF; Cox A; Kagucia W; Elwood D; Henderson S; Wanionek K; Speicher J; Whitehead SS; Pletnev AG
    Vaccine; 2013 Nov; 31(48):5772-7. PubMed ID: 23968769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus).
    Langevin SA; Arroyo J; Monath TP; Komar N
    Am J Trop Med Hyg; 2003 Jul; 69(1):78-80. PubMed ID: 12932102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.
    Woods CW; Sanchez AM; Swamy GK; McClain MT; Harrington L; Freeman D; Poore EA; Slifka DK; Poer DeRaad DE; Amanna IJ; Slifka MK; Cai S; Shahamatdar V; Wierzbicki MR; Amegashie C; Walter EB
    Vaccine; 2019 Jul; 37(30):4222-4230. PubMed ID: 30661836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
    Pierce KK; Whitehead SS; Kirkpatrick BD; Grier PL; Jarvis A; Kenney H; Carmolli MP; Reynolds C; Tibery CM; Lovchik J; Janiak A; Luke CJ; Durbin AP; Pletnev AG
    J Infect Dis; 2017 Jan; 215(1):52-55. PubMed ID: 28077583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of West Nile virus DNA-plasmid vaccination on response to live virus challenge in red-tailed hawks (Buteo jamaicensis).
    Redig PT; Tully TN; Ritchie BW; Roy AF; Baudena MA; Chang GJ
    Am J Vet Res; 2011 Aug; 72(8):1065-70. PubMed ID: 21801064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ChimeriVax-West Nile vaccine.
    Hall RA; Khromykh AA
    Curr Opin Mol Ther; 2007 Oct; 9(5):498-504. PubMed ID: 17932814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects.
    Beasley DW
    Expert Rev Vaccines; 2011 May; 10(5):601-4. PubMed ID: 21604981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.